JPMorgan previews Brepocitinib’s upcoming dermatomyositis readout in 2H on a conference call to be held on June 25 at 11 am. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences Announces $500M Share Repurchase Program
- Roivant Sciences announces $500M share repurchase program
- Optimistic Outlook for Roivant Sciences: Buy Rating Backed by Brepo’s Potential and Financial Opportunities
- Optimistic Outlook for Roivant Sciences Driven by Promising Brepocitinib Results in Phase 3 VALOR Study
- Roivant Sciences’ Growth Potential Highlighted by Upcoming Phase 3 VALOR Study for Brepocitinib